Regeneron And Bayer Announce Start Of Phase 3 Clinical Program In Diabetic Macular Edema
TARRYTOWN, N.Y. and BERLIN, April 8, 2011 /PRNewswire/ --Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that they have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema (DME). The companies are extending their development program for VEGF Trap-Eye in DME after promising results in the global Phase 2 DME program.